Wyburn-Mason disease: Management of a Spetzler-Martin grade 5 arteriovenous malformation with predominant thalamic involvement

Authors: Jovan Dhatt, BS, Karis Houser, Kathryn A Szymanski, BS, Kelly Halderman, BS, Michael Kuwabara, MD

Source: Radiology Case Reports, Vol 20, Iss 3, Pp 1323-1327 (2025)

Subject Terms: Wyburn-Mason disease, Arteriovenous malformation, Trametinib, Thalamus, Spetzler-Martin Grade 5, Ischemia, Medical physics. Medical radiology. Nuclear medicine, R895-920

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S1930043324012937; https://doaj.org/toc/1930-0433

Access URL: https://doaj.org/article/fb8e2f4aca98456bb1dc59feacdccd13

The MEK inhibitor trametinib is effective in inhibiting the growth of canine oral squamous cell carcinoma

Authors: William P. Katt, Cheryl E. Balkman, Scott D. Butler, Michael Byron, Patrick C. Carney, Amy B. Todd-Donato, Matthew E. Drozd, Gerald E. Duhamel, Jacquelyn M. Evans, Nadine Fiani, Jordan C. Ford, Jennifer K. Grenier, Jessica J. Hayward, Kristiina Heikinheimo, Kelly R. Hume, Elizabeth S. Moore, Rishi Puri, Skylar R. Sylvester, Sydney L. Warshaw, Suzin M. Webb, Andrew C. White, Alexandra L. Wright, Richard A. Cerione, Santiago Peralta

Source: Scientific Reports, Vol 15, Iss 1, Pp 1-19 (2025)

Subject Terms: Oral squamous cell carcinoma, Canine cancer, Trametinib, RAS signaling, Medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/2045-2322

Access URL: https://doaj.org/article/4f9065e06f0c403dbfcdf12c73bc500a

Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2

Authors: Satoru Miyazaki, Masato Kitazawa, Satoshi Nakamura, Makoto Koyama, Yuta Yamamoto, Nao Hondo, Masahiro Kataoka, Hirokazu Tanaka, Michiko Takeoka, Daisuke Komatsu, Yuji Soejima

Source: Molecular Oncology, Vol 19, Iss 2, Pp 377-390 (2025)

Subject Terms: fedratinib, KRAS, MRTX1133, pancreatic cancer, sotorasib, trametinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1574-7891; https://doaj.org/toc/1878-0261

Access URL: https://doaj.org/article/d14149042f2f4fd7b6ae31dff45e21ef

Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study

Authors: Nargiz Majidova, Hacı Arak, Faruk Recep Ozalp, Onur Bas, Gulhan Ozcelik Koker, Erkan Buket Ozmarasalı, Yasemin Sagdıc Karateke, Teoman Sakalar, Sendag Yaslikaya, Ilknur Deliktas Onur, Goncagul Akdag, Ali Ogul, Murad Guliyev, Elif Sahin, Ebru Engin Delipoyraz, Ali Alkan, Okan Aydın, Nurullah Ilhan, Ozkan Alan, Sinem Akbas, Yaprak Cağlar, Ali Kaan Guren, Nadiye Sever, Halil Ibrahim Ellez, Fatih Selcukbiricik, Mustafa Muhammed Atcı, Ahmet Bilici, Nebi Serkan Demirci, Tugba Basoglu, Cengiz Karacin, Ismail Oguz Kara, Bulent Yıldız, Turkkan Evrensel, Mustafa Karaca, Omer Dizdar, Elif Atag, Alpaslan Ozgun, Osman Kostek

Source: Scientific Reports, Vol 15, Iss 1, Pp 1-8 (2025)

Subject Terms: Adjuvant therapy, Dabrafenib plus trametinib, Chemotherapy, Immune checkpoint inhibitors, Melanoma, Survival outcomes, Medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/2045-2322

Access URL: https://doaj.org/article/9828f0522bfd4c938176e3ac69348cb2

Establishment and characterization of a new mouse gastric carcinoma cell line, MCC

Authors: Yushen Wang, Xianju Li, Yi Wang, Jun Qin

Source: Cancer Cell International, Vol 25, Iss 1, Pp 1-12 (2025)

Subject Terms: Gastric carcinoma, MCC, Genomic, Proteomic, Trametinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Cytology, QH573-671

File Description: electronic resource

Relation: https://doaj.org/toc/1475-2867

Access URL: https://doaj.org/article/c1f29f7652b34f69ac41c8167b4d6832

Dabrafenib plus trametinib in low-grade versus high-grade gliomas: a systematic review and meta-analysis

Authors: Bardia Hajikarimloo, Mohammad Amin Habibi, Alireza Kooshki, Mohammadamin Sabbagh Alvani, Amir Hossein Zare, Arman Hasanzade, Amir Hessam Zare, Mohammadhosein Akhlaghpasand, Roozbeh Tavanaei, Salem M. Tos

Source: BMC Cancer, Vol 24, Iss 1, Pp 1-17 (2024)

Subject Terms: Dabrafenib, Trametinib, Low-grade glioma, High-grade glioma, BRAF, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/ae1b93b1da7b40659136ab18db03b129

Recurrent melanoma 25 years after initial diagnosis, presenting as metastatic disease early after heart transplantation

Authors: Gal Rubinstein, Benjamin Izar, Diana E. McDonnell, Andrea Fernandez Valledor, Justin A. Fried, Kevin Clerkin, Edward F. Lin, Dor Lotan, Farhana Latif, Gabriel Sayer, Nir Uriel, Jayant K. Raikhelkar

Source: Cardio-Oncology, Vol 10, Iss 1, Pp 1-4 (2024)

Subject Terms: Heart transplantation, Malignant melanoma, Dabrafenib, Trametinib, Diseases of the circulatory (Cardiovascular) system, RC666-701, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2057-3804

Access URL: https://doaj.org/article/0d335aeb221c4937a728f4e1b0d66e9a

Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms

Authors: Arianna Marinello, MD, Claudia Parisi, MD, Damien Vasseur, PhD, David Combarel, PharmD, Juliette Bihoreau, NP, Pernelle Lavaud, MD, Rémy Ezzedine, MD, Lodovica Zullo, MD, Luc Friboulet, PhD, Gerard Zalcman, MD, PhD, Antoine Italiano, MD, PhD, Benjamin Besse, MD, PhD, Mihaela Aldea, MD, PhD

Source: JTO Clinical and Research Reports, Vol 6, Iss 3, Pp 100773- (2025)

Subject Terms: EGFR-mutated NSCLC, RET fusion, BRAF V600E, Selpercatinib, Trametinib, Case report, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364324001437; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/342ea336baed47408d1a5e3b6965bb2f

Trametinib as a targeted treatment in cardiac and lymphatic presentations of Noonan syndrome

Authors: Isabel De Brouchoven, Juan Lorand, Léon Bofferding, Arthur Sorlin, An Van Damme, Olivier Danhaive

Source: Frontiers in Pediatrics, Vol 13 (2025)

Subject Terms: Noonan syndrome, RASopathy, MEK inhibitors, trametinib, congenital pulmonary lymphangiectasia, chylothorax, Pediatrics, RJ1-570

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fped.2025.1475143/full; https://doaj.org/toc/2296-2360

Access URL: https://doaj.org/article/f59d1092114a42aa91e9be22c4a01e59

Integrating MAPK pathway inhibition into standard-of-care therapy for pediatric low-grade glioma

Authors: Erin E. Crotty, Aimee A. Sato, Mohamed S. Abdelbaki

Source: Frontiers in Oncology, Vol 15 (2025)

Subject Terms: pediatric low grade glioma, trametinib, selumetinib, MEK, MAPK pathways, BRAF, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2025.1520316/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/11490beeb4414876ab826ece27bc5af1

A rare case of vision loss caused by leptomeningeal metastasis of lung adenocarcinoma: a case report and literature review

Authors: Zhihua Li, Jian Chu, Wennan Shen, Junnan Chen, Yuemei Dong, Manze Zhang, Nan Zhao, Wei Zhao, Haoran Zha, Ning Wang, Yalin Han, Zhaoxia Li

Source: Frontiers in Oncology, Vol 15 (2025)

Subject Terms: leptomeningeal metastasis, BRAF non-V600E mutation, NSCLC, trametinib, vision loss, case report, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2025.1484383/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/94bad32213a74aabbf4b56c66f35de15

Glutamine transporter inhibitor enhances the sensitivity of NSCLC to trametinib through GSDME-dependent pyroptosis

Authors: Liu, Qingxia ^{a, 1}, Hu, Jinxia ^{a, 1}, Li, Xinzhen ^{a, 1}, Gao, Haiwang ^a, Kong, Dexin ^{a, b, ⁎⁎}, Jin, Meihua ^{a, ⁎}

Source: In Biochemical Pharmacology March 2025 233

Trametinib alleviates lipopolysaccharide-induced acute kidney injury by inhibiting macrophage polarization through the PI3K/Akt pathway

Authors: Zeng, Yingqi ^{a, b}, Yuan, Wenjia ^{a, b}, Feng, Chen ^{a, b}, Peng, Longkai ^{a, b}, Xie, Xubiao ^{a, b}, Peng, Fenghua ^{a, b}, Li, Tengfang ^{a, b}, Lin, Minjie ^c, Zhang, Hedong ^{a, b, ⁎}, Dai, Helong ^{a, b, 1, ⁎}

Source: In Transplant Immunology March 2025 89

Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort

Authors: Swalduz, Aurélie ^{a, ⁎}, Beau-Faller, Michèle ^b, Planchard, David ^c, Mazieres, Julien ^d, Bayle-Bleuez, Sophie ^e, Debieuvre, Didier ^f, Fallet, Vincent ^g, Geier, Margaux ^h, Cortot, Alexis ⁱ, Couraud, Sébastien ^j, Daniel, Catherine ^k, Domblides, Charlotte ^l, Pichon, Eric ^m, Fabre, Elizabeth ⁿ, Larivé, Sébastien ^o, Lerolle, Ulrike ^p, Tomasini, Pascale ^q, Wislez, Marie ^r, Missy, Pascale ^s, Morin, Franck ^s, Westeel, Virginie ^t, Auliac, Jean-Bernard ^u

Source: In Lung Cancer January 2025 199

Clinical response to dabrafenib plus trametinib in BRAF V600E mutated papillary craniopharyngiomas: a case report and literature review

Authors: Paul Hanona, Daniel Ezekwudo, Joseph Anderson

Source: Frontiers in Oncology, Vol 14 (2024)

Subject Terms: papillary, craniopharyngioma, BRAF mutation V600E, dabrafenib, trametinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1464362/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/b4a741bb71e247abb31e82558ed854ab

Extended 73‐month survival in an elderly patient with BRAF V600E‐mutated lung adenocarcinoma: A case report

Authors: Kensuke Namba, Kazutoshi Isobe, Hiroki Wakabayashi, Ryogo Ohashi, Hiromasa Sakurai, Daiki Sakai, Yusuke Irie, Kenta Takashima, Yu Murakami, Kaichi Kaneko, Nobuyuki Hiruta, Yasuo Matsuzawa

Source: Respirology Case Reports, Vol 12, Iss 10, Pp n/a-n/a (2024)

Subject Terms: BRAF V600E mutation, dabrafenib/trametinib, elder, non‐small cell lung cancer, Diseases of the respiratory system, RC705-779

File Description: electronic resource

Relation: https://doaj.org/toc/2051-3380

Access URL: https://doaj.org/article/9dcef2518b7a436daccff34d260194dd

Response to trametinib, hydroxychloroquine, and bevacizumab in a young woman with NRAS-mutated metastatic intrahepatic cholangiocarcinoma: a case report

Authors: Aram A. Musaelyan, Ekaterina M. Anokhina, Alina I. Turdubaeva, Natalia V. Mitiushkina, Anastasia N. Ershova, Anna D. Shestakova, Aigul R. Venina, Evgeny N. Imyanitov, Sergey V. Orlov

Source: Exploration of Targeted Anti-tumor Therapy, Vol 5, Iss 3, Pp 780-788 (2024)

Subject Terms: intrahepatic cholangiocarcinoma, nras mutation, trametinib, hydroxychloroquine, bevacizumab, Internal medicine, RC31-1245

File Description: electronic resource

Relation: https://www.explorationpub.com/Journals/etat/Article/1002246; https://doaj.org/toc/2692-3114

Access URL: https://doaj.org/article/15c6b988128b481890e948ca980a13a8

Targeted treatment in complex lymphatic anomaly: a case of synergistic efficacy of trametinib and sirolimus

Authors: Emmanuel Seront, Antoine Froidure, Nicole Revencu, Valerie Dekeuleneer, Philippe Clapuyt, Dana Dumitriu, Miikka Vikkula, Laurence M. Boon

Source: Orphanet Journal of Rare Diseases, Vol 19, Iss 1, Pp 1-6 (2024)

Subject Terms: Complex lymphatic anomaly, Sirolimus, Trametinib, VASE, Lymphedema, Infection, Medicine

File Description: electronic resource

Relation: https://doaj.org/toc/1750-1172

Access URL: https://doaj.org/article/27565a7accc341e589e0e8225fd143af

Extracellular vesicles promote migration despite BRAF inhibitor treatment in malignant melanoma cells

Authors: Afrodité Németh, Gréta L. Bányai, Nikolett K. Dobos, Tamás Kós, Anikó Gaál, Zoltán Varga, Edit I. Buzás, Delaram Khamari, Magdolna Dank, István Takács, A. Marcell Szász, Tamás Garay

Source: Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-14 (2024)

Subject Terms: Extracellular vesicles, Melanoma, Vemurafenib, Dabrafenib, Trametinib, Single cell tracking, Medicine, Cytology, QH573-671

File Description: electronic resource

Relation: https://doaj.org/toc/1478-811X

Access URL: https://doaj.org/article/82cfcaeb75a74849a5be0051bae737b3

CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma

Authors: Ke Cheng, Zijian Zhou, Qiangxing Chen, Zixin Chen, Yu Cai, He Cai, Shangdi Wu, Pan Gao, Yunqiang Cai, Jin Zhou, Xin Wang, Zhong Wu, Bing Peng

Source: Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)

Subject Terms: PDAC, Trametinib, Palbociclib, Drug resistance, Medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/2045-2322

Access URL: https://doaj.org/article/677acbb956ea4a74afd45acba5093f15